Who Supplies Ofloxacin to India from FINLAND

To import finished pharmaceutical formulations containing Ofloxacin into India, the foreign manufacturer must obtain a Drug Import License from the Directorate General of Foreign Trade (DGFT). The product must be registered with the Central Drugs Standard Control Organisation (CDSCO), which involves submitting Form 40/41 along with the necessary documentation, including a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The registration process typically takes 6 to 12 months. For formulations under HS Code 30049099, a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare is also required.

Imported pharmaceutical formulations must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided to ensure product efficacy and safety. Upon arrival, customs drug inspectors conduct port inspections, including sampling and testing, to verify product quality before clearance.

Recent updates to India's import policies have focused on enhancing domestic manufacturing capabilities and reducing dependency on imports. The Production Linked Incentive (PLI) scheme has been extended to include finished pharmaceutical formulations, offering incentives to domestic manufacturers. While this may impact the volume of imports, it also presents opportunities for foreign suppliers to collaborate with Indian manufacturers under contract manufacturing agreements.

India imports finished Ofloxacin formulations to meet the demand for branded and specialized dosage forms not produced domestically. The market size for Ofloxacin formulations in India is substantial, with a total import value of $295.2 million across 1,094 exporters to 180 countries. This indicates a significant reliance on imports to fulfill domestic demand, especially for specific formulations and packaging.

The Basic Customs Duty (BCD) on finished pharmaceutical formulations under HS Code 30049099 is 10%. The Social Welfare Surcharge (SWS) is 10% of the BCD, resulting in an additional 1% duty. The Integrated Goods and Services Tax (IGST) rate varies based on the specific product classification. There are no exemptions or preferential duty rates for Finland-origin products under this HS code.

Finland's pharmaceutical industry is known for high-quality standards and innovative formulations. Indian buyers may source Ofloxacin formulations from Finland to access patented or specialized dosage forms not available domestically. Other major suppliers include China, Germany, and the United States, but Finland's reputation for quality and compliance with international standards provides a competitive edge.

India imports Ofloxacin formulations from Finland to access high-quality, patented, or specialized dosage forms not produced domestically. Finland's pharmaceutical industry is known for its adherence to international quality standards, making it a reliable source for such formulations.

Compared to other suppliers like China, Germany, and the United States, Finland offers a competitive advantage in terms of product quality and regulatory compliance. While China may offer lower prices, Finland's reputation for quality and adherence to international standards provides a unique selling point.

Potential risks include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, Indian importers should consider diversifying their supplier base and maintaining buffer stocks.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC) or Documents Against Payment (DA/DP).
4. 4Supplier Qualification: Conduct thorough due diligence to ensure supplier reliability and compliance.
5. 5Regulatory Compliance: Stay updated on regulatory changes in both Finland and India to ensure continuous compliance.

1. 1DGFT Import License: Obtain a valid import license from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Register the product with the Central Drugs Standard Control Organisation, including submission of Form 40/41.
3. 3NOC: Secure a No Objection Certificate from the Ministry of Health and Family Welfare.
4. 4Customs Broker: Engage a licensed customs broker for clearance procedures.
5. 5Advance Ruling: Seek an advance ruling for HS Code 30049099 to confirm duty rates and compliance requirements.

1. 1Certificate of Analysis (CoA): Confirming product quality and compliance with Indian standards.
2. 2Certificate of Pharmaceutical Product (CoPP): Indicating GMP compliance and market authorization.
3. 3GMP Certificate: Demonstrating adherence to Good Manufacturing Practices.
4. 4Drug Master File (DMF): Providing detailed information on the manufacturing process.
5. 5Stability Data: Including ICH Zone IVa/IVb stability studies.
6. 6Free Sale Certificate: Indicating unrestricted sale in the country of origin.
7. 7Manufacturer Authorization: Authorizing the exporter to act on behalf of the manufacturer.